2023年第46届圣安东尼奥乳腺癌研讨会（San Antonio Breast Cancer Symposium，SABCS）将于12月5日至9日在美国得克萨斯州圣安东尼奥举行。该会议汇聚了全球约1万名临床医生和专家，是规模最大、最具影响力的乳腺癌研究盛会。
日前，大会公布了本次会议的详细日程及研究题目，150余项中国研究成果入选SABCS POSTER session。【肿瘤资讯】从官网获得现有资讯，将入选POSTER session 2的中国研究信息整理如下，以飨读者。
PO2-01-04 Efficacy and safety of anti-HER2 therapy in neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
作者：Lu Gan，Fangxuan Li，Jialin Su
第一作者单位：The First Affiliated Hospital of Chongqing Medical University
PO2-01-05 Neoadjuvant pyrotinib plus trastuzumab, and chemoterapy in patients with HER2-positive early breast cancer: a real-world study.
作者：Jun Zhou，Rui Wang
第一作者单位：Department of Breast Cancer, The first people's hospital of lianyungang
PO2-02-05 CDK4/6 inhibitor dalpiciclib combined with letrozole as neoadjuvant therapy in postmenopausal patients with hormone receptor-positive, HER2-negative stage II-III breast cancer: a single-arm exploratory trial.
作者：Lina Zhang，Chao Yang，Jie Ma，Yuntao Li，Ruizhen Luo，Jianjun Han，Xiaochun Wang，Zhisheng Zhang，Li Ma，Haifeng Cai，Xiangshun Kong，Zunyi Wang，Xinping Zhou，Yueping Liu，JiaJie Shi，Yanshou Zhang，Meiqi Wang，Jiaxing Wang，Cuizhi Geng
第一作者单位：Breast Center, The Fourth Hospital of Hebei Medical University
PO2-02-07 Clinicopathological Features and Prognostic Role of HER2 Low in Early Breast Cancer: A real world study.
作者：Ziqing Kong，Weihong Zhao
第一作者单位：Department of Medical Oncology, the First Medical Center, Chinese PLA General Hospital
PO2-03-05 Neoadjuvant anthracycline followed by Toripalimab combined with nab-paclitaxel in patients with stage IIA-IIIC triple negative breast cancer (NeoTENNIS): efficacy and safety results of a phase II study.
作者：Min He，Linxiaoxi Ma，Shuang Hao，Benlong Yang，Bingqiu Xiu，Ya-Yun Chi ，Ruo-Hong Shui，Zhong-Hua Wang，Zhi-Ming Shao，Jiong Wu
第一作者单位：Fudan University Shanghai Cancer Center
PO2-03-11 A novel peripheral CD4+ T cell immune network associated with response to PD-1 inhibitor in early-stage triple negative breast cancer.
作者：Zehao Wang，Zhibo Shao，Bingqiu Xiu，Jiong Wu
第一作者单位：Fudan University Shanghai Cancer Center
PO2-04-02 Trends in Disparities and Transitions of target therapy in Patients With ERBB2 Positive Early Breast Cancer in China and the US, 2011 to 2021.
作者：Jianbin Li，Jifang Zhou，Haibo Wang，Zhenzhen liu，Zhimin Fan，Yinhua Liu，Cuizhi Geng，Zefei Jiang
第一作者单位：China Pharmaceutical University
PO2-04-03 BL-M07D1, an antibody-drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study.
作者：Erwei Song，Herui Yao，Meili Sun，Hong Zong，Rongbo Lin，Wen Zou，Muran Ding，Jing Yu，Sa Xiao，Hongwei Wang，Hai Zhu，Martin Olivo，Yi Zhu
第一作者单位：Breast Tumour Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
PO2-04-07 Efficacy and Safety of First-line Therapy in Patients with HER-2 positive Advanced Breast Cancer：A network Meta-analysis of Randomized Controlled Trials.
作者：junxiao wang，Yushuai Yu，Jie Zhang，Chuangui Song
第一作者单位：The Second Hospital of Sanming, China (People's Republic)
PO2-05-01 Famitinib, a multi-targeted receptor tyrosine kinase inhibitor, combined with dalpicilib and fulvestrant in advanced HR-positive and HER2-negative breast cancer.
作者：Min Yan，Mengwei Zhang，Limin Niu，Huimin Lv，Zhenzhen Liu，Huiai zeng，Shengnan Zhao，Huihui Sun，Jing Wang，Yajing Feng，Huajun Li
第一作者单位：Henan Cancer Hospital
PO2-05-12 Retrospective analysis on therapeutic efficacy and predictive indicators of eribulin plus anti-angiogenic drugs for metastatic breast cancer.
作者：Junmei Zhang，Xuezheng Wang，hongjuan Du ，Yan Xue
第一作者单位：Department of Medical Oncology, XI’AN International medical center hospital
PO2-05-13 HER2 status presented an unstable switching from primary to recurrent breast cancer.
作者：Anjie Zhu，Hui-Ping Li
第一作者单位：Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute
PO2-06-09 A prospective phase 2 study on efficacy and safety of AK105, anlotinib combined with nab- paclitaxel (nab-P) as a first-line therapy in patients(pts) with advanced triple-negative breast cancer (TNBC).
作者：Liang Zhang，Tao Sun
第一作者单位：Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and & Institute, Key Laboratory of Liaoning Breast Cancer Research
PO2-06-11 A phase II randomized trial of gemcitabine plus cisplatin(GP) vs gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple-negative breast cancer.
作者：Chengcheng Gong，Yannan Zhao，Leiping Wang，jun Cao，Zhonghua Tao，Ting Li，Mingchuan Zhao，Haitao Miao，Juan Jin，Xichun Hu，Biyun Wang
第一作者单位：Fudan University Shanghai Cancer Center
PO2-06-14 Kynurenine induces senescence reprogramming to promote metastasis in young triple- negative breast cancer.
作者：Cui-Cui Liu，Ke-da Yu
第一作者单位：Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University
PO2-08-02 Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy.
作者：Jin Zhang
第一作者单位：The 3rd Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education
PO2-13-04 Single cell characterization of senescent CD8+ T cell promotes immunotherapy resistance in early-stage triple-negative breast cancer.
作者：Tong Fu，Yi-Yu Chen，Xi Jin，Yi-Zhou Jiang，Zhi- Ming Shao
第一作者单位：Fudan University Shanghai Cancer Center
PO2-15-02 Personalized circulating tumor DNA (ctDNA) monitoring can early identify disease progression and predict prognosis in patients with breast cancer undergoing neoadjuvant therapy.
作者：Yunjiang Liu，Chao Shi，Xiangmei Zhang，Xiaofei Ren，Shang Wu，Yaxian Wang，Yue Che，Zanmei Xu，Fei Pang
第一作者单位：Department of Breast Center, Fourth Hospital of Hebei Medical University
PO2-16-06 Treatment Patterns of Neoadjuvant Therapy in Chinese Patients with HR-Positive/HER2- Positive Early or Locally Advanced Breast Cancer: A Real-World Study Using NCID Data in 2019-2022.
作者：Zhenzhen Liu，Jiujun Zhu，Chengzheng Wang，Zhenduo Lu，Xiuchun Chen，Lianfang Li ，Xianfu Sun，Chongjian Zhang，Jianghua Qiao ，Min Yan
第一作者单位：Department of Breast Disease, Henan Breast Cancer Center. The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
PO2-16-08 Adjuvant Treatment Selection for County-Level Patients with HR+/HER2- Early Breast Cancer in a Real-Life Setting in China.
作者：Yinghua Ji，Honglan Qu，Feidu Zhou，Juan Wang，Qianfu Wu，Guohua Dai，Mengyou Liu，Wenbo He，Wei Liang，Qiuli Meng，Yun Ren ，Guoxiang Luo，Hongjian Wang，Hui Liu，Zien Qin，Yingguo Tian，Huali Tang ，Hongmei Liu，Jun Luo，Zengfeng Yu Guinv Hu Jianzhi Gao Xiang Tan Yi Liu Yuanjiang Zhang Ming Wang Min Zhang，Ping Lu
第一作者单位：The First Affiliated Hospital of Xinxiang Medical University
PO2-17-03 Patient reported outcomes (PROs) and survival with toremifene versus aromatase inhibitors (AI) in patients with moderate/high-risk premenopausal hormone receptor (HR)-positive breast cancer: A real-world study.
作者：Yaping Yang，Fengxia Gan，Wenqian Yang，Yuan Xia，Qiang Liu，Chang Gong
第一作者单位：Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
PO2-17-04 Landscape of young breast cancer under 35 years in China over the past decades: a multicentre retrospective cohort study (YBCC-Catts study).
作者：xue Wang，changfa xia，yu wang，yixin qi，Xiaowei Qi，Jiuda zhao，songqing ye，zixuan lei，Jian Yue，hairong huang，ning liu，wanqing chen，peng yuan，Binghe Xu
第一作者单位：National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
PO2-18-12 Updated Results of a Phase II Study: Neoadjuvant Inetetamab Combined with Pertuzumab, Paclitaxel and Carboplatin for Locally Advanced HER2-Positive Breast Cancer.
作者：Yue Chai，Jiaxuan Liu ，Mingxia Jiang，Maiyue He，Xin Wang，Yipeng Wang，Xue Yang，Jing Wang，Binghe Xu，Qiao Li
第一作者单位：Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
PO2-23-08 High intratumor heterogeneity induced PSME2 confers endocrine resistance via ERα PARylation in hormone receptor-positive and HER2-negative breast cancer.
作者：Li-Ping Ge，Zi-Yu Wang ，Xi Jin，Yi-Zhou Jiang，Zhi-Ming Shao
第一作者单位：Fudan University Shanghai Cancer Center
PO2-23-11 SMAD4 depletion contributes to endocrine therapy resistance by ERBB signaling in HR+HER2- breast cancer.
作者：Kang Li，Dan Shu，Han Li
第一作者单位：The First Affiliated Hospital of Chongqing Medical University
PO2-24-12 Tumor-specific circRNAs elicit anti-tumor immune response via encoding cryptic antigenic peptides.
作者：Di Huang，Jianing Chen，Shicheng Su，Erwei Song
第一作者单位：Sun Yat Sen Memorial Hospital
PO2-25-02 The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple- negative breast cancer.
作者：Hai Wang
作者单位：Fudan University Shanghai Cancer Center
PO2-25-04 Anti-TIGIT upregulate CD226 on CD8+T cell as a potential therapeutic manner in HER2 positive breast cancer.
作者：Liyi Zhang，Qi Zhang，Zehao Wang，Zhibo Shao，Jingyan Xue，Yayun Chi，Bingqiu Xiu，Jiong Wu
第一作者单位：Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China. Department of Oncology, Fudan University Shanghai Medical College
PO2-27-01 TFX06, a next-generation oral CERAN/SERD, shows favorable safety and PK profile, extracranial and intracranial efficacy in patients with ER+/HER2- breast cancer: Preliminary results from a phase 1/2 first-in-human trial.
作者：Zhaojian Fu，Zhiye Zhang，Jia Song，Yang Chen，Douglas Fang，Wei Sha，Jian Zhang，Charles Ding
第一作者单位：VyBio
PO2-27-11 Antitumor efficacy and safety of sacibertinib (Hemay022) in combination with endocrine therapy in patients with ER+ and HER2+ metastatic breast cancer: A phase Ib study.
作者：Hui-Ping Li，Qingyuan Zhang，Ruyan Zhang，Yaxin Liu，Chang Liu，Xianjun Hu
第一作者单位：Department of Medical Oncology, Peking University Cancer Hospital & Institute
Rapid Fire Session: Mini-Oral Presentations、POSTER SPOTLIGHT Session
本文检索了POSTER SESSIONS中第一作者单位为中国单位的研究。如果有任何错误或遗漏，请联系我们进行修改。
http://www.sabcs.org/FullProgram
排版编辑：肿瘤资讯-张薪媛
苏公网安备 32059002004080号
